Popular terms

Autoimmune Disease topics
Autoimmune Disease
Immune Disease
Autoimmune
Autoimmune Diseases
Immune Diseases
Transplant
Infectious Disease
Infectious
Inflammatory Disease
Antagonist
Rheumatoid Arthritis
Proliferative
Nucleotide
Antibodies
Infectious Diseases

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune Disease patents



      

This page is updated frequently with new Autoimmune Disease-related patent applications.




Date/App# patent app List of recent Autoimmune Disease-related patents
05/19/16
20160138021 
 Compositions and methods for treating cancer and other diseases patent thumbnailnew patent Compositions and methods for treating cancer and other diseases
Aptamers and improved aptamers are provided with enhanced efficacy for binding to target molecules in vivo or for treating cancer or other diseases. Such improvements in aptamers are provided that enhance in vivo efficacy such as binding to the target molecule or enhancing anti-cancer activity.
Memorial Sloan Kettering Cancer Center


05/19/16
20160137731 
 Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor patent thumbnailnew patent Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
The present invention is based, in part, on the identification of novel human anti-pd-1, pd-l1, and pd-l2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating pd-1, pd-l1, and/or pd-l2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-pd-1, pd-l1, and pd-l2 antibodies described herein..
Emory University


05/19/16
20160137713 
 Fcrn-specific human antibody and composition for treatment of autoimmune diseases patent thumbnailnew patent Fcrn-specific human antibody and composition for treatment of autoimmune diseases
The present invention relates to a human antibody specific for fcrn that is a receptor with a high affinity for igg, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The fcrn-specific antibody according to the present invention can bind to fcrn non-competitively with igg or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases..
Hanall Biopharma Co., Ltd.


05/19/16
20160137646 
 Novel compounds and uses thereof patent thumbnailnew patent Novel compounds and uses thereof
The present invention provides novel compounds of any one of formulae (i)-(iv), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of formulae (i)-(iv) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.


05/19/16
20160137613 
 Novel anti-inflammatory agents patent thumbnailnew patent Novel anti-inflammatory agents
Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (il-6) and/or vascular cell adhesion molecule-1 (vcam-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation..
Resverlogix Corp.


05/19/16
20160137608 
 Substituted benzoazepines as toll-like receptor modulators patent thumbnailnew patent Substituted benzoazepines as toll-like receptor modulators
Provided are compositions and methods useful for modulation of signaling through the toll-like receptors tlr7 and/or tlr8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease..
Array Biopharma, Inc.


05/19/16
20160136267 
 Sphingoglycolipid analogues patent thumbnailnew patent Sphingoglycolipid analogues
The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.. .
Victoria Link Limited


05/12/16
20160131646 
 Detection and treatment of autoimmune disorders patent thumbnailDetection and treatment of autoimmune disorders
Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (sle) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a pd1 ligand.. .
Seattle Children's Hospital


05/12/16
20160130552 
 Method for obtaining immuno-suppressive dendritic cells patent thumbnailMethod for obtaining immuno-suppressive dendritic cells
The present invention relates to methods for producing immuno-suppressive dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from autoimmune diseases, hypersensitivity diseases, rejection on solid-organ transplantation and/or graft-versus-host disease..
Yale University


05/12/16
20160130360 
 Her2/neu-specific antibodies and methods of using same patent thumbnailHer2/neu-specific antibodies and methods of using same
This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.


05/12/16
20160130343 

Anti-ilt7 antibody


An antibody binding to ipc was obtained by using an animal cell in which a cell membrane protein associatable with ilt7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ilt family molecules and ilt7.
Sbi Biotech Co., Ltd.


05/12/16
20160130333 

Chimeric and humanized anti-histone antibodies


The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.


05/12/16
20160130318 

Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases


The present relates to interleukin 15 (il-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an il-15 mutant polypeptide having the amino acid sequence as set forth in seq id no:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.
Universite D'angers


05/12/16
20160129043 

Composition of mesenchymal stem cells


This invention relates in general to a mesenchymal stem cell (msc) therapy. This invention further relates to the isolation and applications of gingiva derived mesenchymal stem cells.
University Of Southern California


05/12/16
20160129010 

Substituted benzoazepines as toll-like receptor modulators


Provided are compositions and methods useful for modulation of signaling through the toll-like receptors tlr7 and/or tlr8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease..
Array Biopharma, Inc.


05/05/16
20160122768 

Autoimmune disease treatments


There are provided, inter alia, methods and compositions to treat autoimmune disease including invasiveness of fibroblast-like synoviocytes in rheumatoid arthritis.. .
La Jolla Institute For Allergy And Immunology


05/05/16
20160122429 

Anti-tnf- / anti-il-23 bispecific antibodies


Bispecific antibodies are provided that bind tumor necrosis factor alpha (tnfα) and the p19 subunit of interleukin-23 (il-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both tnfα and il-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including inflammatory bowel disease, such as crohn's disease and ulcerative colitis, axial spondyloarthropathy, rheumatoid arthritis and psoriatic arthritis..
Eli Lilly And Company


05/05/16
20160122334 

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..

05/05/16
20160122330 

Piperidinyl benzoimidazole derivatives as mpge-1 inhibitors


The compounds (r)-1-(5-chloro-6-methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1h-benzo[d]imidazol-2-yl)-n-(tetrahydrofuran-3-yl)piperidine-4-carboxamide and (r)-1-(6-chloro-1-methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1h-benzo[d]imidazol-2-yl)-n-(tetrahydrofuran-3-yl)piperidine-4-carboxamide, as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising any one of these compounds. The compounds are useful for the treatment and/or prevention of a disorder selected from an inflammatory disease; an autoimmune disease; pain; a breathing disorder; cancer; a cardiovascular disease; a neurodegenerative disease; a bone disease; a disorder due to familial adenomatous polyposis (fap) condition; overactive bladder; fever; and inflammation-related anorexia..
Novasaid Ab


05/05/16
20160122323 

Inhibitors of cyclin-dependent kinase 7 (cdk7)


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.


05/05/16
20160121039 

Methods for the treatment or prevention of systemic sclerosis


The disclosure is in the field of molecular immunology, more in particular, in the field of the prevention or treatment of autoimmune diseases, more in particular, systemic sclerosis or scleroderma. The disclosure is based on the observation that ssc patients have an elevated plasma level of cxcl4.
Stichting Katholieke Universiteit


04/28/16
20160116469 

Immunologically active polypeptide


Disclosed are immunomodulatory polypeptides that behave as weak tlr2 and tlr4 agonists and as potent competitive antagonists of natural pathogenic ligands for human and murine tlr2 and tlr4, that identify a subset of neutrophils in human peripheral blood leukocytes, and that elicit an unusual induced cytokine profile. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry.
Institute Of Arthritis Research, Llc


04/28/16
20160115232 

Targeting agent antibody conjugates and uses thereof


Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells.
The California Institute For Biomedical Research


04/28/16
20160115227 

Administration of an anti-interleukin 12/23 antibody for treatment of autoimmune disease


The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of ustekinumab is administered to the subject.

04/28/16
20160115188 

Novel alpha-galactosyl ceramide analogs and uses thereof


The present invention is directed to compounds of formula (i) and pharmaceutical compositions comprising compounds of formula (i) and pharmaceutically acceptable carriers. The invention further comprises improved process for the preparation of compounds of formula (i), and the use of compound of formula (i) to induce a specific immune response or to treat an autoimmune disease..
National Chung Hsing Unviersity


04/28/16
20160115153 

Lanthionine synthetase c-like 2-based therapeutics


Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..
Biotherapeutics, Inc.


04/28/16
20160115126 

Indole carboxamide compounds


Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

04/28/16
20160114007 

Composition for preventing or treating autoimmune disease, comprising, as active ingredient, pink1 protein or polynucleotide encoding same


The present invention relates to a composition for preventing or treating an autoimmune disease comprising, as an active ingredient, pink1 protein or polynucleotide encoding the same. The pink1 protein according to the present invention inhibits the activity of th17, promotes the activity of a regulatory t cell (treg), and increases autophagy in treg cells, thereby controlling excessive immune responses.
Catholic University Industry Academic Cooperation Foundation


04/28/16
20160113958 

Modulators of adp-dependent glucokinase (adpgk) and glycerol-3-phosphate dehydrogenase (gpd2) for therapy


Described are compounds capable of modulating (a) the biological activity of adp-dependent glucokinase (adpgk) and/or glycerol-3-phosphate dehydrogenase (gpd2) or (b) the expression of the gene encoding adpgk or gpd2 for use in treating a disease (a) associated with aberrant cell proliferation, e.g., a neoplasm, or (b) of the immune system, e.g., an autoimmune disease.. .
Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Recht


04/21/16
20160109443 

Detection of gluten-specific t-cells


The present invention relates to compositions and methods for visualizing disease-specific t-cells. In particular, the present invention relates to compositions and methods for use in the diagnosis, monitoring of progression, monitoring of response to therapy, and selection of patients for therapy of autoimmune diseases characterized by selective expansion of disease-specific effector memory t-cells..

04/21/16
20160106905 

Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders


This invention uses “targeted apheresis” to treat patients with rheumatoid arthritis and other autoimmune and inflammatory disorders. “targeted apheresis” is a process whereby only the pathogenic and pro-inflammatory elements associated with the disease symptoms are simultaneously and selectively removed from the blood by passing the blood through an extracorporeal affinity device containing selective binding agents.

04/14/16
20160103137 

Method for the analysis of n-glycans attached to immunoglobulin g from human blood plasma and its use


From the results of the analysis, glycan age index (gai) is calculated, and it is useful for: prediction of biological age of a tested individual; monitoring efficacy of methods that slow down the ageing process; monitoring progression of diseases that are developed as a result of the ageing process advancement, like: inflammatory diseases (including atherosclerosis), autoimmune diseases, tumours, diabetes, arthritis, osteoporosis, and alzheimer disease; and evaluation of overall condition/health of a body.. .

04/14/16
20160102132 

Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t-cells


The present invention provides, in particular embodiments, for modified recombinant t cell receptor (tcr) ligands (rtls) comprising a mhc class i or mhc class ii component. The modified rtls have redesigned surface features that preclude or reduce aggregation, wherein the modified molecules retain the ability to bind ag-peptides, target antigen-specific t cells, inhibit t cell proliferation in an ag-specific manner and have utility to treat, inter alia, autoimmune disease and other conditions mediated by antigen-specific t cells in vivo..

04/14/16
20160101189 

Monomers and oligonucleotides comprising cycloaddition adduct(s)


In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression..

04/07/16
20160096891 

Anti-b7-h5 antibodies and their uses


The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the b7-h5 ligand of the b7-h5:cd28h pathway, and to the uses of such molecules in the treatment and diagnosis of autoimmune disease, transplant rejection and other inflammatory diseases.. .
The Johns Hopkins University


04/07/16
20160095910 

Self-assembling synthetic proteins


The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host..

04/07/16
20160095895 

Highly concentrated formulations of soluble fc receptors


The present invention relates to novel formulations of soluble fc receptors and especially to formulations containing high concentrations of soluble fcγriib receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved..
Suppremol Gmbh


04/07/16
20160095839 

Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions


Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases.. .
Caliper Life Sciences, Inc.


04/07/16
20160095835 

Compositions containing omega-3 oil and uses thereof


The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules.
Maine Natural Health Company, Inc.


03/31/16
20160090627 

Compositions for detecting human interferon-alpha subtypes and methods of use


The invention provides highly sensitive, specific and efficient quantitative real-time pcr compositions, methods and assay kits to detect at least one ifn subtype and/or ifn subtype allotypic variants. Primer/probe sets complementary to the coding sequence of an ifn subtype of interest avoid spurious detection of degraded mrna and enhances the correlation between the ifn subtype that is measured by the assays of the invention and the protein that is actually expressed.
United States Department Of Health & Human Services


03/24/16
20160084844 

Methods of identifying glycopeptides recognized by disease-associated auto-antibodies


Methods for identifying glycopeptides and more particularly glycopeptide epitopes that are specifically recognized by disease-associated auto-antibodies are provided. In some aspects the auto-antibodies are cancer-associated or autoimmune disease associated.
Glycozym, Inc.


03/24/16
20160083473 

Bispecific constructs and their use in the treatment of various diseases


The present invention relates to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to il23r-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in treating inflammatory and/or autoimmune diseases and/or cancer.. .
Numab Ag


03/24/16
20160083369 

Heterocyclic compounds and use thereof


Heterocyclic compounds of formula (i) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation.
National Health Research Institutes


03/24/16
20160082017 

Estriol therapy for multiple sclerosis and other autoimmune diseases


The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (ms), rheumatoid arthritis (ra), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis..

03/17/16
20160075999 

Method for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases


A method for enhancing the therapeutic effect of a stem cell on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell.
Gwo Xi Stem Cell Applied Technology Co., Ltd.


03/17/16
20160075790 

Antibody polypeptides that antagonize cd40l


Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Bristol-myers Squibb Company




Autoimmune Disease topics: Autoimmune Disease, Immune Disease, Autoimmune, Autoimmune Diseases, Immune Diseases, Transplant, Infectious Disease, Infectious, Inflammatory Disease, Antagonist, Rheumatoid Arthritis, Proliferative, Nucleotide, Antibodies, Infectious Diseases

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.249

5656

1 - 1 - 104